<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">32789005</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>10</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>10</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">2046-1402</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>9</Volume>
            <PubDate>
              <Year>2020</Year>
            </PubDate>
          </JournalIssue>
          <Title>F1000Research</Title>
          <ISOAbbreviation>F1000Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>A review of advances in the understanding of lupus nephritis pathogenesis as a basis for emerging therapies.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">F1000 Faculty Rev-905</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.12688/f1000research.22438.1</ELocationID>
        <Abstract>
          <AbstractText>Lupus nephritis is an important cause of both acute kidney injury and chronic kidney disease that can result in end-stage renal disease. Its pathogenic mechanisms are characterized by aberrant activation of both innate and adaptive immune responses, dysregulation of inflammatory signaling pathways, and increased cytokine production. Treatment of lupus nephritis remains a challenging issue in the management of systemic lupus erythematosus since the clinical presentation, response to treatment, and prognosis all vary considerably between patients and are influenced by ethnicity, gender, the degree of chronic kidney damage, pharmacogenomics, and non-immunological modulating factors. Elucidation of the various immunopathogenic pathways in lupus nephritis has resulted in the development of novel therapies, including biologics that target specific antigens on B lymphocytes to achieve B cell depletion, agents that modulate B cell proliferation and development, drugs that block co-stimulatory pathways, drugs that target T lymphocytes primarily, and therapies that target complement activation, signaling pathways, pro-inflammatory cytokines, and neutrophil extracellular traps. This review will discuss recent advances in the understanding of disease pathogenesis in lupus nephritis in the context of potential emerging therapies.</AbstractText>
          <CopyrightInformation>Copyright: © 2020 Yung S et al.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Yung</LastName>
            <ForeName>Susan</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, The University of Hong Kong, Pokfulam, Hong Kong.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Yap</LastName>
            <ForeName>Desmond Yh</ForeName>
            <Initials>DY</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, The University of Hong Kong, Pokfulam, Hong Kong.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chan</LastName>
            <ForeName>Tak Mao</ForeName>
            <Initials>TM</Initials>
            <Identifier Source="ORCID">0000-0002-3495-4051</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, The University of Hong Kong, Pokfulam, Hong Kong.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>08</Month>
          <Day>04</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>F1000Res</MedlineTA>
        <NlmUniqueID>101594320</NlmUniqueID>
        <ISSNLinking>2046-1402</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001402" MajorTopicYN="N">B-Lymphocytes</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008180" MajorTopicYN="N">Lupus Erythematosus, Systemic</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008181" MajorTopicYN="N">Lupus Nephritis</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">B cell depletion</Keyword>
        <Keyword MajorTopicYN="Y">emerging therapies</Keyword>
        <Keyword MajorTopicYN="Y">inflammation</Keyword>
        <Keyword MajorTopicYN="Y">lupus nephritis</Keyword>
        <Keyword MajorTopicYN="Y">lupus nephritis pathogenesis</Keyword>
      </KeywordList>
      <CoiStatement>No competing interests were disclosed.No competing interests were disclosed.No competing interests were disclosed.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32789005</ArticleId>
        <ArticleId IdType="pmc">PMC7405261</ArticleId>
        <ArticleId IdType="doi">10.12688/f1000research.22438.1</ArticleId>
        <ArticleId IdType="pii">F1000 Faculty Rev-905</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Cameron JS:
Lupus nephritis.
J Am Soc Nephrol.
1999;10(2):413–24.
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10215343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mohan C, Putterman C:
Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis.
Nat Rev Nephrol.
2015;11(6):329–41.
10.1038/nrneph.2015.33
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrneph.2015.33</ArticleId>
            <ArticleId IdType="pubmed">25825084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chan TM:
Treatment of severe lupus nephritis: The new horizon.
Nat Rev Nephrol.
2015;11(1):46–61.
10.1038/nrneph.2014.215
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrneph.2014.215</ArticleId>
            <ArticleId IdType="pubmed">25421826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cooper GS, Dooley MA, Treadwell EL, et al. :
Hormonal, environmental, and infectious risk factors for developing systemic lupus erythematosus.
Arthritis Rheum.
1998;41(10):1714–24.
10.1002/1529-0131(199810)41:10&lt;1714::AID-ART3&gt;3.0.CO;2-U
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1529-0131(199810)41:10&lt;1714::AID-ART3&gt;3.0.CO;2-U</ArticleId>
            <ArticleId IdType="pubmed">9778212</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rovin BH, Lu L, Zhang X:
A novel interleukin-8 polymorphism is associated with severe systemic lupus erythematosus nephritis.
Kidney Int.
2002;62(1):261–5.
10.1046/j.1523-1755.2002.00438.x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1523-1755.2002.00438.x</ArticleId>
            <ArticleId IdType="pubmed">12081586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yang W, Ng P, Zhao M, et al. :
Population differences in SLE susceptibility genes: STAT4 and BLK, but not PXK, are associated with systemic lupus erythematosus in Hong Kong Chinese.
Genes Immun.
2009;10(3):219–26.
10.1038/gene.2009.1
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/gene.2009.1</ArticleId>
            <ArticleId IdType="pubmed">19225526</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jönsen A, Bengtsson AA, Nived O, et al. :
Gene-environment interactions in the aetiology of systemic lupus erythematosus.
Autoimmunity.
2007;40(8):613–7.
10.1080/08916930701511051
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/08916930701511051</ArticleId>
            <ArticleId IdType="pubmed">18075795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Seredkina N, Zykova SN, Rekvig OP:
Progression of Murine Lupus Nephritis Is Linked to Acquired Renal Dnase1 Deficiency and Not to Up-Regulated Apoptosis.
Am J Pathol.
2009;175(1):97–106.
10.2353/ajpath.2009.080943

</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2353/ajpath.2009.080943</ArticleId>
            <ArticleId IdType="pmc">PMC2708798</ArticleId>
            <ArticleId IdType="pubmed">19528352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tiller T, Tsuiji M, Yurasov S, et al. :
Autoreactivity in human IgG
+ memory B cells.
Immunity.
2007;26(2):205–13.
10.1016/j.immuni.2007.01.009

</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2007.01.009</ArticleId>
            <ArticleId IdType="pmc">PMC1839941</ArticleId>
            <ArticleId IdType="pubmed">17306569</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Herlands RA, Christensen SR, Sweet RA, et al. :
T cell-independent and toll-like receptor-dependent antigen-driven activation of autoreactive B cells.
Immunity.
2008;29(2):249–60.
10.1016/j.immuni.2008.06.009

</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2008.06.009</ArticleId>
            <ArticleId IdType="pmc">PMC4106705</ArticleId>
            <ArticleId IdType="pubmed">18691914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Odegard JM, Marks BR, DiPlacido LD, et al. :
ICOS-dependent extrafollicular helper T cells elicit IgG production via IL-21 in systemic autoimmunity.
J Exp Med.
2008;205(12):2873–86.
10.1084/jem.20080840

</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20080840</ArticleId>
            <ArticleId IdType="pmc">PMC2585848</ArticleId>
            <ArticleId IdType="pubmed">18981236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tipton CM, Fucile CF, Darce J, et al. :
Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus.
Nat Immunol.
2015;16(7):755–65.
10.1038/ni.3175

</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.3175</ArticleId>
            <ArticleId IdType="pmc">PMC4512288</ArticleId>
            <ArticleId IdType="pubmed">26006014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hoffman W, Lakkis FG, Chalasani G:
B Cells, Antibodies, and More.
Clin J Am Soc Nephrol.
2016;11(1):137–54.
10.2215/CJN.09430915

</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2215/CJN.09430915</ArticleId>
            <ArticleId IdType="pmc">PMC4702236</ArticleId>
            <ArticleId IdType="pubmed">26700440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Avery DT, Bryant VL, Ma CS, et al. :
IL-21-Induced Isotype Switching to IgG and IgA by Human Naive B Cells Is Differentially Regulated by IL-4.
J Immunol.
2008;181(3):1767–79.
10.4049/jimmunol.181.3.1767
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.181.3.1767</ArticleId>
            <ArticleId IdType="pubmed">18641314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Vlahakos DV, Foster MH, Adams S, et al. :
Anti-DNA antibodies form immune deposits at distinct glomerular and vascular sites.
Kidney Int.
1992;41(6):1690–700.
10.1038/ki.1992.242
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ki.1992.242</ArticleId>
            <ArticleId IdType="pubmed">1501424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tsao BP, Ohnishi K, Cheroutre H, et al. :
Failed self-tolerance and autoimmunity in IgG anti-DNA transgenic mice.
J Immunol.
1992;149(1):350–8.
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1607661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Riley JK, Sliwkowski MX:
CD20: A gene in search of a function.
Semin Oncol.
2000;27(6 Suppl 12):17–24.
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11225995</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tsokos GC:
B Cells, Be Gone — B-Cell Depletion in the Treatment of Rheumatoid Arthritis.
N Engl J Med.
2004;350(25):2546–8.
10.1056/NEJMp048114
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMp048114</ArticleId>
            <ArticleId IdType="pubmed">15201410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cordeiro AC, Isenberg DA:
Novel therapies in lupus - focus on nephritis.
Acta Reumatol Port.
2008;33(2):157–69.
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18604181</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Edwards JCW, Szczepanski L, Szechinski J, et al. :
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.
N Engl J Med.
2004;350(25):2572–81.
10.1056/NEJMoa032534
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa032534</ArticleId>
            <ArticleId IdType="pubmed">15201414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bekar KW, Owen T, Dunn R, et al. :
Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus.
Arthritis Rheum.
2010;62(8):2443–57.
10.1002/art.27515

</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.27515</ArticleId>
            <ArticleId IdType="pmc">PMC2920998</ArticleId>
            <ArticleId IdType="pubmed">20506300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rovin BH, Furie R, Latinis K, et al. :
Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study.
Arthritis Rheum.
2012;64(4):1215–26.
10.1002/art.34359
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.34359</ArticleId>
            <ArticleId IdType="pubmed">22231479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tobinai K, Klein C, Oya N, et al. :
A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies.
Adv Ther.
2017;34(2):324–56.
10.1007/s12325-016-0451-1

</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12325-016-0451-1</ArticleId>
            <ArticleId IdType="pmc">PMC5331088</ArticleId>
            <ArticleId IdType="pubmed">28004361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Freeman CL, Sehn LH:
A tale of two antibodies: Obinutuzumab versus rituximab.
Br J Haematol.
2018;182(1):29–45.
10.1111/bjh.15232
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bjh.15232</ArticleId>
            <ArticleId IdType="pubmed">29741753</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Segerer S, Schlöndorff D:
B cells and tertiary lymphoid organs in renal inflammation.
Kidney Int.
2008;73(5):533–7.
10.1038/sj.ki.5002734
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.ki.5002734</ArticleId>
            <ArticleId IdType="pubmed">18094677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Elward K, Griffiths M, Mizuno M, et al. :
CD46 Plays a Key Role in Tailoring Innate Immune Recognition of Apoptotic and Necrotic Cells.
J Biol Chem.
2005;280(43):36342–54.
10.1074/jbc.M506579200
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M506579200</ArticleId>
            <ArticleId IdType="pubmed">16087667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kawano M, Seya T, Koni I, et al. :
Elevated serum levels of soluble membrane cofactor protein (CD46, MCP) in patients with systemic lupus erythematosus (SLE).
Clin Exp Immunol.
1999;116(3):542–6.
10.1046/j.1365-2249.1999.00917.x

</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1365-2249.1999.00917.x</ArticleId>
            <ArticleId IdType="pmc">PMC1905304</ArticleId>
            <ArticleId IdType="pubmed">10361248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Weidenbusch M, Römmele C, Schröttle A, et al. :
Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis.
Nephrol Dial Transplant.
2013;28(1):106–11.
10.1093/ndt/gfs285
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ndt/gfs285</ArticleId>
            <ArticleId IdType="pubmed">22764193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Díaz-Lagares C, Croca S, Sangle S, et al. :
Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts.
Autoimmun Rev.
2012;11(5):357–64.
10.1016/j.autrev.2011.10.009
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.autrev.2011.10.009</ArticleId>
            <ArticleId IdType="pubmed">22032879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Moroni G, Gallelli B, Sinico RA, et al. :
Rituximab versus oral cyclophosphamide for treatment of relapses of proliferative lupus nephritis: A clinical observational study.
Ann Rheum Dis.
2012;71(10):1751–2.
10.1136/annrheumdis-2012-201442
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2012-201442</ArticleId>
            <ArticleId IdType="pubmed">22586177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Condon MB, Ashby D, Pepper RJ, et al. :
Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids.
Ann Rheum Dis.
2013;72(8):1280–6.
10.1136/annrheumdis-2012-202844
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2012-202844</ArticleId>
            <ArticleId IdType="pubmed">23740227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pepper R, Griffith M, Kirwan C, et al. :
Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids.
Nephrol Dial Transplant.
2009;24(12):3717–23.
10.1093/ndt/gfp336
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ndt/gfp336</ArticleId>
            <ArticleId IdType="pubmed">19617257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Furie R, Aroca G, Alvarez A, et al. :
A phase II randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of obinutuzumab or placebo in combination with mycophenolate mofetil in patients with active class III or IV lupus nephritis.
Arthritis Rheumatol.
2019;71: [Abstract].
Reference Source
</Citation>
        </Reference>
        <Reference>
          <Citation>
Rovin B, Furie R, Aroca G, et al. :
B-cell depletion and response in a randomized, controlled trial of obinutuzumab for proliferative lupus nephritis.
Kidney Int Rep.
2020;5(3):S352 [Abstract]
Reference Source
</Citation>
        </Reference>
        <Reference>
          <Citation>
Navarra SV, Guzmán RM, Gallacher AE, et al. :
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial.
Lancet.
2011;377(9767):721–31.
10.1016/S0140-6736(10)61354-2
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(10)61354-2</ArticleId>
            <ArticleId IdType="pubmed">21296403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Furie R, Petri M, Zamani O, et al. :
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
Arthritis Rheum.
2011;63(12):3918–30.
10.1002/art.30613

</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.30613</ArticleId>
            <ArticleId IdType="pmc">PMC5007058</ArticleId>
            <ArticleId IdType="pubmed">22127708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dooley MA, Houssiau F, Aranow C, et al. :
Effect of belimumab treatment on renal outcomes: Results from the phase 3 belimumab clinical trials in patients with SLE.
Lupus.
2012;22(1):63–72.
10.1177/0961203312465781
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0961203312465781</ArticleId>
            <ArticleId IdType="pubmed">23263865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Stohl W, Hiepe F, Latinis KM, et al. :
Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus.
Arthritis Rheum.
2012;64(7):2328–37.
10.1002/art.34400

</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.34400</ArticleId>
            <ArticleId IdType="pmc">PMC3350827</ArticleId>
            <ArticleId IdType="pubmed">22275291</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
GSK announces positive headline results in phase 3 study of Benlysta in patients with lupus nephritis. 


 2019 Reference Source</Citation>
        </Reference>
        <Reference>
          <Citation>
Isenberg DA, Petri M, Kalunian K, et al. :
Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: Results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.
Ann Rheum Dis.
2016;75(2):323–31.
10.1136/annrheumdis-2015-207653
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2015-207653</ArticleId>
            <ArticleId IdType="pubmed">26338095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Merrill JT, van Vollenhoven RF, Buyon JP, et al. :
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: Results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.
Ann Rheum Dis.
2016;75(2):332–40.
10.1136/annrheumdis-2015-207654
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2015-207654</ArticleId>
            <ArticleId IdType="pubmed">26293163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rovin BH, Dooley MA, Radhakrishnan J, et al. :
The impact of tabalumab on the kidney in systemic lupus erythematosus: Results from two phase 3 randomized, clinical trials.
Lupus.
2016;25(14):1597–601.
10.1177/0961203316650734
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0961203316650734</ArticleId>
            <ArticleId IdType="pubmed">27220348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ginzler EM, Wax S, Rajeswaran A, et al. :
Atacicept in combination with MMF and corticosteroids in lupus nephritis: Results of a prematurely terminated trial.
Arthritis Res Ther.
2012;14(1):R33.
10.1186/ar3738

</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/ar3738</ArticleId>
            <ArticleId IdType="pmc">PMC3392829</ArticleId>
            <ArticleId IdType="pubmed">22325903</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wu D, Li J, Xu D, et al. :
A human recombinant fusion protein targeting B lymphocyte stimulator (BlyS) and a proliferation-Inducing ligand (APRIL), telitacicept (RC18), in systemic lupus erythematosus (SLE): results of a phase 2b study.
Arthritis Rheumatol.
2019;71 [Abstract]
Reference Source
</Citation>
        </Reference>
        <Reference>
          <Citation>
Dall'Era M, Aranow C, Byron M, et al. :
Phase 2 trial of induction therapy with anti-CD20 (RITUXIMAB) followed by maintenance therapy with anti-BAFF (BELIMUMAB) in patients with active lupus nephritis.
Ann Rheum Dis.
2018;77:690 [Abstract]
Reference Source
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kraaij T, Kamerling SWA, de Rooij ENM, et al. :
The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus.
J Autoimmun.
2018;91:45–54.
10.1016/j.jaut.2018.03.003
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaut.2018.03.003</ArticleId>
            <ArticleId IdType="pubmed">29636274</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Teng YKO, Bruce IN, Diamond B, et al. :
Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
BMJ Open.
2019;9(3):e025687.
10.1136/bmjopen-2018-025687

</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmjopen-2018-025687</ArticleId>
            <ArticleId IdType="pmc">PMC6475247</ArticleId>
            <ArticleId IdType="pubmed">30898822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Merrill J, June J, Koumpouras F, et al. :
Phase 2, double-blind, randomized, placebo-controlled study of a reversible B cell inhibitor, XmAb5871, in systemic lupus erythematosus (SLE).
Ann Rheum Dis.
2019;78:761–62.
10.1136/annrheumdis-2019-eular.4234
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2019-eular.4234</ArticleId>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Alexander T, Sarfert R, Klotsche J, et al. :
The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus.
Ann Rheum Dis.
2015;74(7):1474–8.
10.1136/annrheumdis-2014-206016

</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2014-206016</ArticleId>
            <ArticleId IdType="pmc">PMC4484251</ArticleId>
            <ArticleId IdType="pubmed">25710470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhang H, Liu Z, Huang L, et al. :
The short-term efficacy of bortezomib combined with glucocorticoids for the treatment of refractory lupus nephritis.
Lupus.
2017;26(9):952–8.
10.1177/0961203316686703
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0961203316686703</ArticleId>
            <ArticleId IdType="pubmed">28059023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Furie R, Bomba D, Dall'era M, et al. :
Treatment of systemic lupus erythematosus patients with the immunoproteasome inhibitor KZR-616: results from the first 2 cohorts of an open-label phase 1b dose escalation trial.
Ann Rheum Dis.
2019;78:776–77[Abstract].
10.1136/annrheumdis-2019-eular.1955
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2019-eular.1955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Georgopoulos K, Winandy S, Avitahl N:
The role of the Ikaros gene in lymphocyte development and homeostasis.
Annu Rev Immunol.
1997;15:155–76.
10.1146/annurev.immunol.15.1.155
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev.immunol.15.1.155</ArticleId>
            <ArticleId IdType="pubmed">9143685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
John LB, Ward AC:
The Ikaros gene family: Transcriptional regulators of hematopoiesis and immunity.
Mol Immunol.
2011;48(9–10):1272–8.
10.1016/j.molimm.2011.03.006
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molimm.2011.03.006</ArticleId>
            <ArticleId IdType="pubmed">21477865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hu SJ, Wen Ll, Hu X, et al. :

IKZF1: A critical role in the pathogenesis of systemic lupus erythematosus?
Mod Rheumatol.
2013;23(2):205–9.
10.1007/s10165-012-0706-x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10165-012-0706-x</ArticleId>
            <ArticleId IdType="pubmed">22782532</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wang JH, Avitahl N, Cariappa A, et al. :

Aiolos Regulates B Cell Activation and Maturation to Effector State.
Immunity.
1998;9(4):543–53.
10.1016/s1074-7613(00)80637-8
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s1074-7613(00)80637-8</ArticleId>
            <ArticleId IdType="pubmed">9806640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nakayama Y, Kosek J, Capone L, et al. :
Aiolos Overexpression in Systemic Lupus Erythematosus B Cell Subtypes and BAFF-Induced Memory B Cell Differentiation Are Reduced by CC-220 Modulation of Cereblon Activity.
J Immunol.
2017;199(7):2388–407.
10.4049/jimmunol.1601725

</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1601725</ArticleId>
            <ArticleId IdType="pmc">PMC5602157</ArticleId>
            <ArticleId IdType="pubmed">28848067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Schafer PH, Ye Y, Wu L, et al. :
Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: Immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus.
Ann Rheum Dis.
2018;77(10):1516–23.
10.1136/annrheumdis-2017-212916

</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2017-212916</ArticleId>
            <ArticleId IdType="pmc">PMC6161670</ArticleId>
            <ArticleId IdType="pubmed">29945920</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Furie R, Werth VP, Gaudy A, et al. :
A randomized, placebo-controlled, double-blind, ascending-dose, safety, and pharmacokinetics study of CC-220 in subjects with systemic lupus erythematosus.
Arthritis Rheumatol.
2017;69[Abstract].
Reference Source
</Citation>
        </Reference>
        <Reference>
          <Citation>
Werth VP, Furie R, Gaudy A, et al. :
CC-220 decreases B-cell subsets and plasmacytoid dendritic cells in systemic lupus erythematosus (SLE) patients and is associated with skin improvement: pharmacodynamic results from a phase IIa proof of concept study.
Arthritis Rheumatol.
2017;69[Abstract].
Reference Source
</Citation>
        </Reference>
        <Reference>
          <Citation>
Mak A, Kow NY:
The pathology of T cells in systemic lupus erythematosus.
J Immunol Res.
2014;2014:419029.
10.1155/2014/419029

</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2014/419029</ArticleId>
            <ArticleId IdType="pmc">PMC4017881</ArticleId>
            <ArticleId IdType="pubmed">24864268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dutta D, Barr VA, Akpan I, et al. :
Recruitment of calcineurin to the TCR positively regulates T cell activation.
Nat Immunol.
2017;18(2):196–204.
10.1038/ni.3640

</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.3640</ArticleId>
            <ArticleId IdType="pmc">PMC6352896</ArticleId>
            <ArticleId IdType="pubmed">27941787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ekberg H, van Gelder T, Kaplan B, et al. :
Relationship of tacrolimus exposure and mycophenolate mofetil dose with renal function after renal transplantation.
Transplantation.
2011;92(1):82–7.
10.1097/TP.0b013e31821fad06
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/TP.0b013e31821fad06</ArticleId>
            <ArticleId IdType="pubmed">21562449</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fu J, Wang Z, Lee K, et al. :
Transcriptomic analysis uncovers novel synergistic mechanisms in combination therapy for lupus nephritis.
Kidney Int.
2018;93(2):416–29.
10.1016/j.kint.2017.08.031
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.kint.2017.08.031</ArticleId>
            <ArticleId IdType="pubmed">29102373</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Faul C, Donnelly M, Merscher-Gomez S, et al. :
The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A.
Nat Med.
2008;14(9):931–8.
10.1038/nm.1857

</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.1857</ArticleId>
            <ArticleId IdType="pmc">PMC4109287</ArticleId>
            <ArticleId IdType="pubmed">18724379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Coward RJM, Foster RR, Patton D, et al. :
Nephrotic Plasma Alters Slit Diaphragm–Dependent Signaling and Translocates Nephrin, Podocin, and CD2 Associated Protein in Cultured Human Podocytes.
J Am Soc Nephrol.
2005;16(3):629–37.
10.1681/ASN.2004030172
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1681/ASN.2004030172</ArticleId>
            <ArticleId IdType="pubmed">15659563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chen W, Tang X, Liu Q, et al. :
Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: A multicenter randomized clinical trial.
Am J Kidney Dis.
2011;57(2):235–44.
10.1053/j.ajkd.2010.08.036
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.ajkd.2010.08.036</ArticleId>
            <ArticleId IdType="pubmed">21177013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Liu Z, Zhang H, Liu Z, et al. :
Multitarget Therapy for Induction Treatment of Lupus Nephritis: A Randomized Trial.
Ann Intern Med.
2015;162(1):18–26.
10.7326/M14-1030
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7326/M14-1030</ArticleId>
            <ArticleId IdType="pubmed">25383558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mok CC, Ying KY, Yim CW, et al. :
Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: A randomised controlled trial and long-term follow-up.
Ann Rheum Dis.
2016;75(1):30–6.
10.1136/annrheumdis-2014-206456
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2014-206456</ArticleId>
            <ArticleId IdType="pubmed">25550339</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhang H, Liu Z, Zhou M, et al. :
Multitarget Therapy for Maintenance Treatment of Lupus Nephritis.
 J Am Soc Nephrol.
2017;28(12):3671–8.
10.1681/ASN.2017030263

</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1681/ASN.2017030263</ArticleId>
            <ArticleId IdType="pmc">PMC5698076</ArticleId>
            <ArticleId IdType="pubmed">28760751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Choi CB, Won S, Bae SC:
Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis.
Lupus.
2018;27(6):1007–11.
10.1177/0961203318758505
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0961203318758505</ArticleId>
            <ArticleId IdType="pubmed">29448881</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Park DJ, Kang JH, Lee KE, et al. :
Efficacy and safety of mycophenolate mofetil and tacrolimus combination therapy in patients with lupus nephritis: A nationwide multicentre study.
Clin Exp Rheumatol.
2019;37(1):89–96.
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29998829</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tanaka H, Watanabe S, Aizawa-Yashiro T, et al. :
Long-Term Tacrolimus-Based Immunosuppressive Treatment for Young Patients with Lupus Nephritis: A Prospective Study in Daily Clinical Practice.
 Nephron Clin Pract.
2013;121(3–4):c165–c173.
10.1159/000346149
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000346149</ArticleId>
            <ArticleId IdType="pubmed">23327881</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kise T, Yoshimura H, Fukuyama S, et al. :
Successful treatment with mycophenolate mofetil and tacrolimus in juvenile severe lupus nephritis.
 Case Rep Pediatr.
2015;2015:651803.
10.1155/2015/651803

</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2015/651803</ArticleId>
            <ArticleId IdType="pmc">PMC4346693</ArticleId>
            <ArticleId IdType="pubmed">25785217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dall'Era M, Cisternas MG, Smilek DE, et al. :
Predictors of Long-Term Renal Outcome in Lupus Nephritis Trials: Lessons Learned from the Euro-Lupus Nephritis Cohort.
 Arthritis Rheumatol.
2015;67(5):1305–13.
10.1002/art.39026
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.39026</ArticleId>
            <ArticleId IdType="pubmed">25605554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chan TM:
Preventing renal failure in patients with severe lupus nephritis.
Kidney Int Suppl.
2005; (94):S116–9.
10.1111/j.1523-1755.2005.09427.x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1523-1755.2005.09427.x</ArticleId>
            <ArticleId IdType="pubmed">15752227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yap DYH, Ma MKM, Mok MMY, et al. :
Long-term data on tacrolimus treatment in lupus nephritis.
Rheumatology (Oxford).
2014;53(12):2232–7.
10.1093/rheumatology/keu265
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/keu265</ArticleId>
            <ArticleId IdType="pubmed">24996908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Praga M, Barrio V, Juárez GF, et al. :
Tacrolimus monotherapy in membranous nephropathy: A randomized controlled trial.
Kidney Int.
2007;71(9):924–30.
10.1038/sj.ki.5002215
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.ki.5002215</ArticleId>
            <ArticleId IdType="pubmed">17377504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Austin HA, Illei GG, Braun MJ, et al. :
Randomized, Controlled Trial of Prednisone, Cyclophosphamide, and Cyclosporine in Lupus Membranous Nephropathy.
J Am Soc Nephrol.
2009;20(4):901–11.
10.1681/ASN.2008060665

</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1681/ASN.2008060665</ArticleId>
            <ArticleId IdType="pmc">PMC2663831</ArticleId>
            <ArticleId IdType="pubmed">19297556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mok CC:
Calcineurin inhibitors in systemic lupus erythematosus.
Best Pract Res Clin Rheumatol.
2017;31(3):429–38.
10.1016/j.berh.2017.09.010
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.berh.2017.09.010</ArticleId>
            <ArticleId IdType="pubmed">29224682</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sin FE, Isenberg D:
An evaluation of voclosporin for the treatment of lupus nephritis.
Expert Opin Pharmacother.
2018;19(14):1613–21.
10.1080/14656566.2018.1516751
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14656566.2018.1516751</ArticleId>
            <ArticleId IdType="pubmed">30207816</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dörner T, Furie R:
Novel paradigms in systemic lupus erythematosus.
Lancet.
2019;393(10188):2344–58.
10.1016/S0140-6736(19)30546-X
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(19)30546-X</ArticleId>
            <ArticleId IdType="pubmed">31180031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rovin BH, Solomons N, Pendergraft WF, et al. :
A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis.
Kidney Int.
2019;95(1):219–31.
10.1016/j.kint.2018.08.025
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.kint.2018.08.025</ArticleId>
            <ArticleId IdType="pubmed">30420324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gibson KL, Parikh S, Saxena A, et al. :
AURORA phase 3 trial demonstrates voclosporin statistical superiority over standard of care in lupus nephritis (LN).
Am J Kidney Dis.
2020;75(5):819[Abstract].
Reference Source
</Citation>
        </Reference>
        <Reference>
          <Citation>
Mihara M, Tan I, Chuzhin Y, et al. :
CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus.
J Clin Invest.
2000;106(1):91–101.
10.1172/JCI9244

</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI9244</ArticleId>
            <ArticleId IdType="pmc">PMC314360</ArticleId>
            <ArticleId IdType="pubmed">10880052</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Waterhouse P, Penninger JM, Timms E, et al. :
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in
Ctla-4.
Science.
1995;270(5238):985–8.
10.1126/science.270.5238.985
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.270.5238.985</ArticleId>
            <ArticleId IdType="pubmed">7481803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dall'Era M, Davis J:
CTLA4Ig: A novel inhibitor of costimulation.
Lupus.
2004;13(5):372–6.
10.1191/0961203303lu1029oa
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1191/0961203303lu1029oa</ArticleId>
            <ArticleId IdType="pubmed">15230295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Daikh DI, Wofsy D:
Cutting Edge: Reversal of Murine Lupus Nephritis with CTLA4Ig and Cyclophosphamide.
 J Immunol.
2001;166(5):2913–6.
10.4049/jimmunol.166.5.2913
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.166.5.2913</ArticleId>
            <ArticleId IdType="pubmed">11207238</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Furie R, Nicholls K, Cheng TT, et al. :
Efficacy and safety of abatacept in lupus nephritis: A twelve-month, randomized, double-blind study.
 Arthritis Rheumatol.
2014;66(2):379–89.
10.1002/art.38260
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.38260</ArticleId>
            <ArticleId IdType="pubmed">24504810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Furie R, Dooley MA, Wofsy D, et al. :
A phase III randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of abatacept or placebo on standard of care in patients with active class III or IV lupus nephritis.
Ann Rheum Dis.
2020;77:176[Abstract].
Reference Source
</Citation>
        </Reference>
        <Reference>
          <Citation>
Wofsy D, Hillson JL, Diamond B:
Abatacept for lupus nephritis: Alternative definitions of complete response support conflicting conclusions.
Arthritis Rheum.
2012;64(11):3660–5.
10.1002/art.34624
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.34624</ArticleId>
            <ArticleId IdType="pubmed">22806274</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yu CC, Fornoni A, Weins A, et al. :
Abatacept in B7-1-positive proteinuric kidney disease.
N Engl J Med.
2013;369(25):2416–23.
10.1056/NEJMoa1304572

</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1304572</ArticleId>
            <ArticleId IdType="pmc">PMC3951406</ArticleId>
            <ArticleId IdType="pubmed">24206430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Reiser J, von Gersdorff G, Loos M, et al. :
Induction of B7-1 in podocytes is associated with nephrotic syndrome.
J Clin Invest.
2004;113(10):1390–7.
10.1172/JCI20402

</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI20402</ArticleId>
            <ArticleId IdType="pmc">PMC406528</ArticleId>
            <ArticleId IdType="pubmed">15146236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Furie R, Bruce I, Dorner T, et al. :
Efficacy and safety of dapirolizumab pegol (DZP) in patients with moderately to severely active systemic lupus erythematosus (SLE): A randomized, placebo (PBO)-controlled study.
Ann Rheum Dis.
2019;78:775–76.
Reference Source
</Citation>
        </Reference>
        <Reference>
          <Citation>
Koga T, Ichinose K, Kawakami A, et al. :
The role of IL-17 in systemic lupus erythematosus and its potential as a therapeutic target.
Expert Rev Clin Immunol.
2019;15(6):629–37.
10.1080/1744666X.2019.1593141
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/1744666X.2019.1593141</ArticleId>
            <ArticleId IdType="pubmed">30874446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhang C, Chan CCY, Cheung KF, et al. :
Effect of mycophenolate and rapamycin on renal fibrosis in lupus nephritis.
Clin Sci (Lond).
2019;133(15):1721–44.
10.1042/CS20190536
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1042/CS20190536</ArticleId>
            <ArticleId IdType="pubmed">31358596</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lui SL, Yung S, Tsang R, et al. :
Rapamycin prevents the development of nephritis in lupus-prone NZB/W F
1 mice.
Lupus.
2008;17(4):305–13.
10.1177/0961203307088289
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0961203307088289</ArticleId>
            <ArticleId IdType="pubmed">18413412</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Stylianou K, Petrakis I, Mavroeidi V, et al. :
The PI3K/Akt/mTOR pathway is activated in murine lupus nephritis and downregulated by rapamycin.
Nephrol Dial Transplant.
2011;26(2):498–508.
10.1093/ndt/gfq496
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ndt/gfq496</ArticleId>
            <ArticleId IdType="pubmed">20709738</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Alperovich G, Rama I, Lloberas N, et al. :
New immunosuppresor strategies in the treatment of murine lupus nephritis.
Lupus.
2007;16(1):18–24.
10.1177/0961203306073136
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0961203306073136</ArticleId>
            <ArticleId IdType="pubmed">17283580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lui SL, Tsang R, Chan KW, et al. :
Rapamycin attenuates the severity of established nephritis in lupus-prone NZB/W F
1 mice.
Nephrol Dial Transplant.
2008;23(9):2768–76.
10.1093/ndt/gfn216
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ndt/gfn216</ArticleId>
            <ArticleId IdType="pubmed">18445640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lai ZW, Kelly R, Winans T, et al. :
Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: A single-arm, open-label, phase 1/2 trial.
Lancet.
2018;391(10126):1186–96.
10.1016/S0140-6736(18)30485-9

</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(18)30485-9</ArticleId>
            <ArticleId IdType="pmc">PMC5891154</ArticleId>
            <ArticleId IdType="pubmed">29551338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yap DYH, Ma MKM, Tang CS, et al. :
Proliferation signal inhibitors in the treatment of lupus nephritis: Preliminary experience.
Nephrology (Carlton).
2012;17(8):676–80.
10.1111/j.1440-1797.2012.01646.x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1440-1797.2012.01646.x</ArticleId>
            <ArticleId IdType="pubmed">22817609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yap DYH, Tang C, Chan GCW, et al. :
Longterm Data on Sirolimus Treatment in Patients with Lupus Nephritis.
J Rheumatol.
2018;45(12):1663–70.
10.3899/jrheum.180507
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3899/jrheum.180507</ArticleId>
            <ArticleId IdType="pubmed">30275264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wallace DJ, Furie RA, Tanaka Y, et al. :
Baricitinib for systemic lupus erythematosus: A double-blind, randomised, placebo-controlled, phase 2 trial.
Lancet.
2018;392(10143):222–31.
10.1016/S0140-6736(18)31363-1
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(18)31363-1</ArticleId>
            <ArticleId IdType="pubmed">30043749</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kahl L, Patel J, Layton M, et al. :
Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus.
Lupus.
2016;25(13):1420–30.
10.1177/0961203316640910
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0961203316640910</ArticleId>
            <ArticleId IdType="pubmed">27055521</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
van Vollenhoven RF, Layton M, Kahl L, et al. :
DRESS syndrome and reversible liver function abnormalities in patients with systemic lupus erythematosus treated with the highly selective JAK-1 inhibitor GSK2586184.
Lupus.
2015;24(6):648–9.
10.1177/0961203315573347
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0961203315573347</ArticleId>
            <ArticleId IdType="pubmed">25724932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Singhal S, Shah V, Crater C, et al. :
Oral selective tyrosine kinase 2 (TYK2) inhibition with BMS-986165 in patients with systemic lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study (PAISLEY).
Lupus Sci Med.
2019;6(Suppl 1):A5–A6 [Abstract].
10.1136/lupus-2019-lsm.5
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/lupus-2019-lsm.5</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chalmers SA, Glynn E, Garcia SJ, et al. :
BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis.
Clin Immunol.
2018;197:205–18.
10.1016/j.clim.2018.10.008

</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clim.2018.10.008</ArticleId>
            <ArticleId IdType="pmc">PMC6384222</ArticleId>
            <ArticleId IdType="pubmed">30339790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Isenberg D, Furie R, Jones N, et al. :
Efficacy, safety, and pharmacodynamic effects of the Bruton’s tyrosine kinase inhibitor, fenebrutinib (GDC-0853), in moderate to severe systemic lupus erythematosus: results of a phase 2 randomized controlled trial.
Arthritis Rheumatol.
2019;71(suppl 10):[Abstract]
Reference Source
</Citation>
        </Reference>
        <Reference>
          <Citation>
Furie R, Khamashta M, Merrill JT, et al. :
Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.
Arthritis Rheumatol.
2017;69(2):376–86.
10.1002/art.39962

</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.39962</ArticleId>
            <ArticleId IdType="pmc">PMC5299497</ArticleId>
            <ArticleId IdType="pubmed">28130918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Furie RA, Morand EF, Bruce IN, et al. :
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): A randomised, controlled, phase 3 trial.
Lancet Rheumatol.
2019;1(4):e208–e219.
10.1016/S2665-9913(19)30076-1
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2665-9913(19)30076-1</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Morand EF, Furie R, Tanaka Y, et al. :
Trial of Anifrolumab in Active Systemic Lupus Erythematosus.
N Engl J Med.
2020;382(3):211–21.
10.1056/NEJMoa1912196
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1912196</ArticleId>
            <ArticleId IdType="pubmed">31851795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Humrich JY, Morbach H, Undeutsch R, et al. :
Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus.
Proc Natl Acad Sci U S A.
2010;107(1):204–9.
10.1073/pnas.0903158107

</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0903158107</ArticleId>
            <ArticleId IdType="pmc">PMC2806746</ArticleId>
            <ArticleId IdType="pubmed">20018660</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Humrich JY, Riemekasten G:
Low-dose IL-2 therapy - a complex scenario that remains to be further explored.
Nat Rev Rheumatol.
2017;13(6):386.
10.1038/nrrheum.2017.71
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrrheum.2017.71</ArticleId>
            <ArticleId IdType="pubmed">28490788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
He J, Zhang X, Wei Y, et al. :
Low-dose interleukin-2 treatment selectively modulates CD4
+ T cell subsets in patients with systemic lupus erythematosus.
Nat Med.
2016;22(9):991–3.
10.1038/nm.4148
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.4148</ArticleId>
            <ArticleId IdType="pubmed">27500725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
von Spee-Mayer C, Siegert E, Abdirama D, et al. :
Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus.
Ann Rheum Dis.
2016;75(7):1407–15.
10.1136/annrheumdis-2015-207776
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2015-207776</ArticleId>
            <ArticleId IdType="pubmed">26324847</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
He J, Zhang R, Shao M, et al. :
Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: A randomised, double-blind, placebo-controlled trial.
Ann Rheum Dis.
2019;79(1):141–9.
10.1136/annrheumdis-2019-215396

</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2019-215396</ArticleId>
            <ArticleId IdType="pmc">PMC6937406</ArticleId>
            <ArticleId IdType="pubmed">31537547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Thurman JM, Nester CM:
All Things Complement.
Clin J Am Soc Nephrol.
2016;11(10):1856–66.
10.2215/CJN.01710216

</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2215/CJN.01710216</ArticleId>
            <ArticleId IdType="pmc">PMC5053787</ArticleId>
            <ArticleId IdType="pubmed">27340286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Trouw LA, Pickering MC, Blom AM:
The complement system as a potential therapeutic target in rheumatic disease.
Nat Rev Rheumatol.
2017;13(9):538–47.
10.1038/nrrheum.2017.125
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrrheum.2017.125</ArticleId>
            <ArticleId IdType="pubmed">28794515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Simon-Tillaux N, Chauvet S, El mehdi D, et al. :
APL-2 prevents both C3 and C5 convertase formation and activity: a potential therapeutic for renal diseases.
J Am Soc Nephrol.
2019;30:918 [Abstract].</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dixon BP, Greenbaum LA, Huang L, et al. :
C3 inhibition with APL-2 targets the underlying disease process of C3G complement hyperactivity and improves proteinuria.
J Am Soc Nephrol.
2019;30:676 [Abstract].</Citation>
        </Reference>
        <Reference>
          <Citation>
Apellis stopping development of APL-2 for lupus nephritis after completion of phase 2 trial.2019. 
Reference Source
</Citation>
        </Reference>
        <Reference>
          <Citation>
Wang Y, Hu Q, Madri JA, et al. :
Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5.
Proc Natl Acad Sci U S A.
1996;93(16):8563–8.
10.1073/pnas.93.16.8563

</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.93.16.8563</ArticleId>
            <ArticleId IdType="pmc">PMC38712</ArticleId>
            <ArticleId IdType="pubmed">8710910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sciascia S, Radin M, Yazdany J, et al. :
Expanding the therapeutic options for renal involvement in lupus: Eculizumab, available evidence.
Rheumatol Int.
2017;37(8):1249–55.
10.1007/s00296-017-3686-5
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00296-017-3686-5</ArticleId>
            <ArticleId IdType="pubmed">28258475</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Furie R, Matis L, Rollins SA, et al. :
A single dose, placebo controlled, double blind, phase I study of the humanized anti-C5 antibody h5G1.1 in patients with systemic lupus erythematosus.
Arthritis Rheum.
2004;50:[Abstract].</Citation>
        </Reference>
        <Reference>
          <Citation>
Bao L, Cunningham PN, Quigg RJ:
Complement in Lupus Nephritis: New Perspectives.
Kidney Dis (Basel).
2015;1(2):91–9.
10.1159/000431278

</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000431278</ArticleId>
            <ArticleId IdType="pmc">PMC4934819</ArticleId>
            <ArticleId IdType="pubmed">27536669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zuber J, Fakhouri F, Roumenina LT, et al. :
Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies.
Nat Rev Nephrol.
2012;8(11):643–57.
10.1038/nrneph.2012.214
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrneph.2012.214</ArticleId>
            <ArticleId IdType="pubmed">23026949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Strakhan M, Hurtado-Sbordoni M, Galeas N, et al. :
36-year-old female with catastrophic antiphospholipid syndrome treated with eculizumab: A case report and review of literature.
Case Rep Hematol.
2014;2014:704371.
10.1155/2014/704371

</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2014/704371</ArticleId>
            <ArticleId IdType="pmc">PMC4214168</ArticleId>
            <ArticleId IdType="pubmed">25389502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pickering MC, Ismajli M, Condon MB, et al. :
Eculizumab as Rescue Therapy in Severe Resistant Lupus Nephritis.
Rheumatology (Oxford).
2015;54(12):2286–8.
10.1093/rheumatology/kev307

</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/kev307</ArticleId>
            <ArticleId IdType="pmc">PMC4643725</ArticleId>
            <ArticleId IdType="pubmed">26316577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Song D, Guo WY, Wang FM, et al. :
Complement Alternative Pathway׳s Activation in Patients With Lupus Nephritis.
Am J Med Sci.
2017;353(3):247–57.
10.1016/j.amjms.2017.01.005
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.amjms.2017.01.005</ArticleId>
            <ArticleId IdType="pubmed">28262211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Watanabe H, Garnier G, Circolo A, et al. :
Modulation of Renal Disease in MRL/
lpr Mice Genetically Deficient in the Alternative Complement Pathway Factor B.
J Immunol.
2000;164(2):786–94.
10.4049/jimmunol.164.2.786
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.164.2.786</ArticleId>
            <ArticleId IdType="pubmed">10623824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Schubart A, Anderson K, Mainolfi N, et al. :
Small-molecule factor B inhibitor for the treatment of complement-mediated diseases.
Proc Natl Acad Sci U S A.
2019;116(16):7926–31.
10.1073/pnas.1820892116

</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1820892116</ArticleId>
            <ArticleId IdType="pmc">PMC6475383</ArticleId>
            <ArticleId IdType="pubmed">30926668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mainolfi N, Ehara T, Karki RG, et al. :
Discovery of 4-((2
S,4
S)-4-Ethoxy-1-((5-methoxy-7-methyl-1
H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases.
J Med Chem.
2020;63(11):5697–722.
10.1021/acs.jmedchem.9b01870
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.jmedchem.9b01870</ArticleId>
            <ArticleId IdType="pubmed">32073845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Omeros reports more positive data in OMS721 phase 2 trial in renal diseases.2017. 
Reference Source
</Citation>
        </Reference>
        <Reference>
          <Citation>
Complement-mediated disease: Lupus nephritis.2020. 
Reference Source
</Citation>
        </Reference>
        <Reference>
          <Citation>
Mantovani A, Cassatella MA, Costantini C, et al. :
Neutrophils in the activation and regulation of innate and adaptive immunity.
Nat Rev Immunol.
2011;11(5):519–31.
10.1038/nri3024
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri3024</ArticleId>
            <ArticleId IdType="pubmed">21785456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Brinkmann V, Zychlinsky A:
Neutrophil extracellular traps: Is immunity the second function of chromatin?
J Cell Biol.
2012;198(5):773–83.
10.1083/jcb.201203170

</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1083/jcb.201203170</ArticleId>
            <ArticleId IdType="pmc">PMC3432757</ArticleId>
            <ArticleId IdType="pubmed">22945932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Garcia-Romo GS, Caielli S, Vega B, et al. :
Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus.
Sci Transl Med.
2011;3(73):73ra20.
10.1126/scitranslmed.3001201

</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.3001201</ArticleId>
            <ArticleId IdType="pmc">PMC3143837</ArticleId>
            <ArticleId IdType="pubmed">21389264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lood C, Blanco LP, Purmalek MM, et al. :
Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease.
Nat Med.
2016;22(2):146–53.
10.1038/nm.4027

</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.4027</ArticleId>
            <ArticleId IdType="pmc">PMC4742415</ArticleId>
            <ArticleId IdType="pubmed">26779811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jeannin P, Jaillon S, Delneste Y:
Pattern recognition receptors in the immune response against dying cells.
Curr Opin Immunol.
2008;20(5):530–7.
10.1016/j.coi.2008.04.013
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.coi.2008.04.013</ArticleId>
            <ArticleId IdType="pubmed">18555676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hakkim A, Fürnrohr BG, Amann K, et al. :
Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis.
Proc Natl Acad Sci U S A.
2010;107(21):9813–8.
10.1073/pnas.0909927107

</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0909927107</ArticleId>
            <ArticleId IdType="pmc">PMC2906830</ArticleId>
            <ArticleId IdType="pubmed">20439745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Knight JS, Subramanian V, O'Dell AA, et al. :
Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/
lpr mice.
Ann Rheum Dis.
2015;74(12):2199–206.
10.1136/annrheumdis-2014-205365

</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2014-205365</ArticleId>
            <ArticleId IdType="pmc">PMC4320672</ArticleId>
            <ArticleId IdType="pubmed">25104775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Macanovic M, Sinicropi D, Shak S, et al. :
The treatment of systemic lupus erythematosus (SLE) in NZB/W F
1 hybrid mice; studies with recombinant murine DNase and with dexamethasone.
Clin Exp Immunol.
1996;106(2):243–52.
10.1046/j.1365-2249.1996.d01-839.x

</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1365-2249.1996.d01-839.x</ArticleId>
            <ArticleId IdType="pmc">PMC2200591</ArticleId>
            <ArticleId IdType="pubmed">8918569</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nakamura T, Ebihara I, Tomino Y, et al. :
Effect of a specific endothelin A receptor antagonist on murine lupus nephritis.
Kidney Int.
1995;47(2):481–9.
10.1038/ki.1995.61
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ki.1995.61</ArticleId>
            <ArticleId IdType="pubmed">7723234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Furumoto Y, Smith CK, Blanco L, et al. :
Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction.
Arthritis Rheumatol.
2017;69(1):148–60.
10.1002/art.39818

</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.39818</ArticleId>
            <ArticleId IdType="pmc">PMC5195893</ArticleId>
            <ArticleId IdType="pubmed">27429362</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wang H, Li T, Chen S, et al. :
Neutrophil Extracellular Trap Mitochondrial DNA and Its Autoantibody in Systemic Lupus Erythematosus and a Proof-of-Concept Trial of Metformin.
Arthritis Rheumatol.
2015;67(12):3190–200.
10.1002/art.39296
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.39296</ArticleId>
            <ArticleId IdType="pubmed">26245802</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
White WI, Seto NL, Playford MP, et al. :
Alteration of mediators of vascular inflammation by anifrolumab in the phase iib muse study in sle.
Ann Rheum Dis.
2018;77(Suppl 2):136–37. [Abstract].
10.1136/annrheumdis-2018-eular.3541
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2018-eular.3541</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
